Tag Archives: IVF

Upcoming Bioarray’s Webinars

The most innovative genetic testing for IVF

Don’t miss our next FREE WEBINARS. We will discuss about our most innovative reproductive genetics tests.

Speaker: Luis A. Alcaraz, PhD – Bioarray’s Scientific Director

Non-invasive PGT-A

niPGT-A as an alternative to trophectoderm biopsy

👉 ‍When: June 15

🕑 Time: 2:00 PM Central European Time

🇬🇧 Language: English

⌚ Duration: 30 minutes

Register at the following link for the non-invasive PGT-A webinar: https://bit.ly/3NdTC4u

MicroVE and BioER

MicroVE: Analysis of the microbiome of the vagina and endometrium.

BioER: Determination of the implantation window through transcriptomics

👉 ‍When: June 22

🕑 Time: 2:00 PM Central European Time

🇬🇧 Language: English

👉 Duration: 30 minutes

Register at the following link for the MicroVE and BioER webinar: https://bit.ly/3M97eNm

Don’t miss them!!!

Bioarray au VIème Congrès de la Société Marocaine de Médecine de la Reproduction et de médecine fœtale (SMMR)

 

 

 

 

 

Bioarray a le plaisir de vous annoncer que nous serons présent au VIème Congrès de la Société Marocaine de Médecine de la Reproduction et de médecine fœtale (SMMR), du 9 au 11 Juin à l’hôtel Hyatt Regency à Casablanca.

Bioarray aura un stand et participera aussi avec un symposium présenté par notre Directeur Médicale le Dr Luis A. Alcaraz “Association between oral and fecal microbiota and the reproductive tract microbiome”.

Symposium Bioarray: le 10 juin de 10h à 10h30 dans la salle Plénière.

Nous serons ravis de vous accueillir sur notre stand et de vous présenter toute notre gamme de tests génétiques de la reproduction. 🧬

Sous le thème : « HUGE STEPS AND INNOVATIONS ON ART» ce Congrès sera une occasion pour une mise au point de tout ce qui se passe dans les domaines de l’AMP, de la chirurgie, de la reproduction et de la médecine fœtale qui sont en pleine mutation.

Au plaisir de vous voir à Casablanca!

Bioarray’s new matching platform for IVF

The new matching platform is a web solution for carrying out genetic matching in IVF treatments. It is specially designed for patients and donors who have previously performed the Bioarray Advance™ Carrier Panel. It is very simple to use.

With this platform, our clients will be able to automatically know if two people are compatible or if they have a high risk of conceiving a child affected by a genetic disease, based on previous genetic studies carried out on each member of the couple. Knowing about a high-risk situation enables the necessary actions to be programmed to eliminate said risk.

Thanks to this platform, IVF clinics will be able to make matchings of their choice, with the aim of maximizing compatibility in the selection of donors, reducing the risk of transmission of genetic diseases.

Our platform currently offers three types of genetic matching:

– Complete Matching:
The complete panel of 1500 genes from the Bioarray Advance ™ Carrier Panel is analized. Ideal for patients or those clinics that prefer to have all the information.

– High Frequency Matching:
Only the genes of a reduced panel chosen by the center are studied. Ideal for patients or those clinics that prefer to study only the most prevalent genes.

– High Frequency Matching X-linked:
The genes of a reduced panel at the choice of the center are studied, as well as all the genes associated with X-linked diseases of the complete panel. Ideal for ovum donors.

MicroVE Vaginal and Endometrial Microbiota and BioER Endometrial Receptivity- Webinar Replay 17/06

Below you can watch our Webinar Replay about the MicroVE and BioER tests, presented by our speaker Dr. Luis A. Alcaraz, PhD.

 

 

Our MicroVE tests analyse the vaginal and endometrial microbiome to ensure that the female reproductive system is in good health.
BioER detects the implantation window to schedule the optimal implantation date and increase the chances of pregnancy.

 

Genetically abnormal human oocytes are more common than we thought

A current study published in the American Journal of Human Genetics, carried out by a team at Washington State University has shown that around 7% of the time oocytes have an unbalanced number of chromosomes. This is due to failures in recombination during the process of meiosis: when genetic material from the maternal and paternal copies of each chromosome are exchanged before cell division, to produce oocytes with half the genetic material.

‘We have known for a long time that advancing maternal age increases the likelihood of chromosomally abnormal eggs, but this observation demonstrates that many chromosome errors have nothing to do with maternal age,’ says Professor Terry Hassold, team leader of the study. ‘They are, instead, errors that are extremely common in our species, for reasons that are unclear.

As expected, after fertilization, chromosomally abnormal oocytes can result in embryos with unbalanced numbers of chromosomes. This is something that can be analysed nowadays thanks to some techniques used in assisted reproduction.

Preimplantation Genetic Testing Aneuploidy (PGT-A) is a test used for IVF procedures in which the embryo´s genome is analysed by NGS screening. This shows whether each embryo has an unbalanced number of chromosomes (aneuploidies) or not, in order to select the most viable one and increase probability of implantation.

Bioarray pioneered the application of NGS to PGT-A in 2014 and is since then providing this analysis to European and South American IVF centres, with great clinical outcome.